Opens in a new tab

GLP-1 Weight Loss and Menopause Hormone Therapy: What Sandy, Utah Women Need to Know 

A,Woman,In,A,Black,Dress,Holding,An,Ozempic,Pen,
June 22, 2026
Hormones

A clinical look at why most GLP-1 weight loss is short-lived for women over 40, what recent Mayo Clinic research says about combining hormone therapy with semaglutide and tirzepatide, and how DEXA-verified care at our Sandy, Utah clinic changes the long-term outcome. 

Every week at our Sandy, Utah clinic, a woman walks in for a DEXA scan after months on a GLP-1 medication. She got the prescription through a telehealth service, or another local provider, and now she wants to see what has actually happened to her body. I would give a lot to never have to have these conversations again. 

Her weight is down. Sometimes dramatically. Her clothes fit, her friends are telling her she looks great, and her primary care doc is high-fiving her at the annual checkup. Then we run the scan. More often than I would like, nearly half of what she lost was muscle. 

Key Takeaways 

  • Up to 40 percent of GLP-1-induced weight loss can be lean mass, particularly muscle. The exact figure depends on the patient, the protocol, and what she is doing alongside the medication. 
  • Postmenopausal women on tirzepatide who also use hormone therapy lose about 19 percent of their body weight on average, compared to about 14 percent for those without hormone therapy. That is roughly a 35 percent relative improvement, per Mayo Clinic research published in The Lancet Obstetrics, Gynaecology, and Women’s Health (January 2026). 
  • Women aged 50 to 64 are the heaviest users of GLP-1 medications of any group in the United States, with 20 percent reporting current or past use, per the 2025 RAND American Life Panel. Most of them are not having their body composition measured. 
  • A DEXA scan is the standard tool for measuring lean mass loss during GLP-1 therapy. Without one, you cannot know whether your weight loss is helping or harming you. 
  • At Revitalize Medical Solutions in Sandy, Utah, we do not prescribe GLP-1 medications outside our comprehensive program. The medication is one tool inside a system that includes hormone optimization, body composition tracking, protein and strength training guidance, and a clear off-ramp. 

Contents 

  1. The problem nobody told them about 
  1. Why the timing is especially bad for women in midlife 
  1. What recent research says about doing it differently 
  1. What this looks like in our Sandy, Utah office 
  1. Questions to ask your provider before you start 
  1. Why we wrote this 

1. The problem nobody told them about 

If you are on a GLP-1 medication, semaglutide (the active ingredient in Ozempic and Wegovy) or tirzepatide (Mounjaro and Zepbound), your body does not get to decide where the weight comes off. It comes off everywhere: some fat, some muscle, some water. The ratio matters more than almost anyone is talking about. 

Recent research published in Nature Reviews Endocrinology documents what we see clinically. Up to 40 percent of GLP-1-induced weight loss can be lean mass, particularly muscle, with other studies putting the number closer to 20 to 30 percent. The exact figure depends on the patient, the protocol, and what she is doing alongside the medication. Even at the low end, that floor is high enough that nobody on these drugs should be ignoring it. 

This matters more for women than men, and it matters most for women in perimenopause and menopause. Here is why. 

Key insight: The medication does not let you choose what you lose. Without measurement, you do not know whether you are losing fat or muscle. With muscle losses this high, that question matters more than the number on the scale. 

2. Why the timing is especially bad for women in midlife 

Perimenopause and menopause are already the years when women lose muscle the fastest. Estrogen drops, progesterone drops, testosterone drops, and the body’s signal to maintain muscle weakens. Women in their forties and fifties already lose roughly 1 percent of their lean muscle per year without intervention. 

There is a second problem we see clinically that the published literature is just starting to catch up with. When a woman’s hormones are in the chaos phase of perimenopause and early menopause, GLP-1 medications often do not work very well in the first place. Estrogen, progesterone, thyroid, and cortisol all sit upstream of metabolic response. When they are dysregulated, the medication has to fight a system that is actively defending fat stores. We routinely see women who have been on semaglutide or tirzepatide for months at another clinic with very little weight loss to show for it. Their providers blame compliance. The real problem is unmanaged hormones. 

Now layer the muscle problem on top of that. The medication suppresses appetite, which is how it works in the first place, and it also reduces the amount of protein you naturally consume. Protein is the single most important nutrient for protecting muscle. So you have a midlife woman whose hormones are already telling her body to shed muscle, taking a medication that further reduces her protein intake, often without anyone monitoring what is happening to her lean mass. 

The result is what the clinical literature calls sarcopenic obesity: lower weight on the scale, but worse body composition than before. Less muscle, slower metabolism, higher risk of frailty, falls, insulin resistance, and weight regain when she eventually stops the medication. 

“Lower weight on the scale but worse body composition than before. That is not the win people think they are getting.”  — Nicole Kelly, PA-C, Medical Director 

3. What recent research says about doing it differently 

The story changes when women use hormone therapy alongside their GLP-1. 

In 2024, researchers at the Mayo Clinic published a study in the journal Menopause looking at postmenopausal women on semaglutide, comparing those who used hormone therapy to those who did not. At every checkpoint (3, 6, 9, and 12 months) the women on hormone therapy lost more weight, and the effect held up after adjusting for confounders. 

In January 2026, Mayo published the full study in The Lancet Obstetrics, Gynaecology, and Women’s Health. Postmenopausal women on hormone therapy lost about 19 percent of their body weight on tirzepatide on average, while those without hormone therapy lost about 14 percent. The women on hormone therapy saw outcomes that matched what younger, premenopausal women experienced. The women without hormone therapy did not. And 45 percent of the hormone therapy group achieved at least 20 percent body weight loss, compared to 18 percent of those without. 

Important caveat: this was an observational study, not a randomized trial. The researchers explicitly say they cannot claim hormone therapy caused the additional weight loss. It is possible that women using hormone therapy were already engaged in healthier behaviors, or that menopause symptom relief improved sleep and quality of life, making it easier to engage with dietary and physical activity changes. The association is real and statistically significant. The mechanism still has to be confirmed. 

Either way, that association is not a small difference. It is the difference between weight loss that lasts and weight loss that does not. 

Key insight: The Mayo data does not prove hormone therapy causes more weight loss on tirzepatide, but it does show that postmenopausal women using hormone therapy alongside tirzepatide consistently outperform postmenopausal women on the medication alone. The association is strong enough to act on while the mechanism is being studied. 

4. What this looks like in our Sandy, Utah office 

We have been treating women this way for years, before the research caught up. Hormone optimization, GLP-1 medications when clinically indicated, DEXA scans to track what is actually changing in the body, and protein and strength training built into the protocol. That comprehensive approach is the foundation of our Female Balance and Beauty program, which is how most of our patients work with us. 

What we want you to understand is this: the GLP-1 is one tool inside a comprehensive program. We do not write standalone semaglutide prescriptions and send people on their way. We do not compete with telehealth pill-mill services and we do not want to. 

We use the medication when it is the right tool. We optimize hormones to make the medication work better and to protect what matters. We measure body composition with DEXA so we actually know what is happening, not just what the bathroom scale says. And we build a program around protein, strength training, sleep, and stress that gives the patient something to maintain when the medication eventually tapers. 

A patient story from our Sandy office (details adjusted to protect privacy): a postmenopausal woman in her early fifties came to us after a frustrating run with a GLP-1 medication through another provider. She had been on it for months and almost no weight had come off. Her hormones were in the middle of menopausal chaos and nobody was managing them. We started her on the full program. Hormone optimization first, GLP-1 added as the right tool inside the protocol, DEXA tracking from day one, protein and strength training built in. Over the next year and a half she lost more than 55 pounds. The DEXA breakdown is the part that matters: about 45 pounds of fat and 11 pounds of lean mass. That is roughly an 80/20 fat-to-muscle ratio, at the favorable end of what the published GLP-1 literature reports (20 to 40 percent muscle loss is typical without comprehensive care). Without hormone optimization layered into the protocol, we would have expected her closer to the 40 percent end of that range. Here is what we will cover in our companion article on postmenopausal bone health: her bone density actually increased during this period. Not held steady. Increased. That is unusual on GLP-1 therapy and it matters enormously for women whose bone density typically drops up to 20 percent in the decade after menopause if left untreated. 

5. Questions to ask your provider before you start 

If you are considering a GLP-1 medication and you are a woman over 40, these are the questions that matter. 

Are we going to track body composition, not just weight? 

The bathroom scale does not tell you what tissue you are losing. A DEXA scan does. If your provider does not have access to one, that is worth knowing before you start. 

Are my hormones part of the picture? 

A weight loss plan that ignores estrogen, progesterone, and testosterone in a midlife woman is not a complete plan. Hormone optimization is not optional for sustainable results, it is the foundation. And in many cases, unmanaged hormones are the reason the medication is not working in the first place. 

What is my protein and strength training plan? 

Without both, you will lose more muscle than necessary. This is not optional either. 

What is the off-ramp? 

What happens when you stop the medication? If your provider does not have a clear answer, you do not have a real plan, you have a prescription. 

Key insight: A real GLP-1 plan answers four questions before the first injection. Body composition tracking. Hormone optimization. Protein and strength training. The off-ramp. If any of those four are missing, you are not getting comprehensive care. 

6. Why we wrote this 

We are not anti-GLP-1. These medications are remarkable when they are used correctly inside a real program of care. What we are against is the way they are being prescribed to women in midlife by services that are not measuring outcomes, are not optimizing hormones, and are not building anything sustainable. The women who come into our Sandy office for DEXA scans after being on semaglutide elsewhere deserved better than what they got. 

If you are in the Salt Lake City area and you are considering GLP-1 weight loss, or you are already on it and want to know what is actually happening in your body, we would like to help. 

The Bottom Line 

GLP-1 medications work. Most providers prescribing them are not measuring whether the weight you lose is fat or muscle, and for women in perimenopause and menopause, the muscle loss problem is severe enough that ignoring it can leave you worse off metabolically than where you started. The Mayo Clinic research consistently shows that postmenopausal women using hormone therapy alongside tirzepatide outperform those without. Comprehensive care, meaning hormone optimization plus DEXA measurement plus protein and strength training plus a clear medication off-ramp, is the difference between weight loss that lasts and weight loss that does not. If your current GLP-1 plan does not include all four, it is not a plan. 

Frequently Asked Questions 

Does hormone therapy actually cause more weight loss on a GLP-1 medication? 

The Mayo Clinic research shows a strong, statistically significant association: postmenopausal women on hormone therapy lost about 19 percent of their body weight on tirzepatide on average, compared to 14 percent for those not on hormone therapy. Because this was observational rather than randomized, the researchers were explicit that they cannot say hormone therapy caused the difference. The association may be partially driven by hormone therapy directly, partially by improvements in sleep and adherence that come with menopause symptom relief, and partially by selection effects in who chooses hormone therapy in the first place. The association is real. The mechanism is still being confirmed. 

How much muscle do you actually lose on a GLP-1? 

Up to 40 percent of weight lost on GLP-1 medications can be lean mass, including muscle, per a 2025 Nature Reviews Endocrinology review. Other studies put the figure at 20 to 30 percent. The exact percentage depends on the medication, the patient’s baseline body composition, the rate of weight loss, protein intake, and resistance training behavior. Without a DEXA scan, you cannot know what your specific ratio is. 

My GLP-1 is not working. What should I check? 

If you are a woman over 40 and you have been on a GLP-1 medication for months with little weight loss, the most common reason we see clinically is unmanaged hormones. Estrogen, progesterone, thyroid, and cortisol all influence how your body responds to the medication. If those are in chaos, the medication is fighting a losing battle. A comprehensive hormone panel and a DEXA scan are the right starting points. 

Can I just take more protein and lift weights to prevent muscle loss? 

Higher protein intake (typically 1.2 to 1.6 grams per kilogram of body weight per day) and resistance training are the foundations of muscle preservation on a GLP-1. They reduce muscle loss but rarely eliminate it, especially in women in perimenopause and menopause whose hormonal environment is already pushing toward muscle loss. The combination of hormone optimization plus protein plus strength training plus DEXA tracking is what we have found gives the most consistent body composition outcomes. 

Why does this hit women in menopause harder than younger women? 

Perimenopause and menopause involve declines in estrogen, progesterone, and testosterone, all of which support muscle maintenance. Women in their forties and fifties are already losing roughly 1 percent of lean muscle per year without intervention. Adding a medication that reduces appetite (and therefore protein intake) compounds the natural loss. Pre-menopausal and perimenopausal women in the Mayo tirzepatide study did not show the same hormone-therapy-related performance gap because their endogenous hormones were still doing the work. Postmenopausal women without hormone therapy underperformed every other group. 

Is compounded semaglutide safe? Should I get it from a telehealth service? 

Compounded semaglutide is available legally through 503A pharmacies in specific clinical scenarios, such as a documented allergy to an inactive ingredient in the FDA-approved version, or a dose not commercially available. The FDA shortage list designation that made widespread compounding routine ended in February 2025, and the FDA is currently proposing to exclude semaglutide from the 503B bulks list (public comment period through June 29, 2026). The legal landscape is active. Beyond legality, the bigger question is whether a service that just sends you a prescription is actually building anything sustainable. Without hormone work, body composition tracking, and a structured off-ramp, you are setting yourself up for the muscle loss and rebound problem described above. 

What is a DEXA scan and how is it different from a regular body fat measurement? 

DEXA (dual-energy X-ray absorptiometry) is the clinical gold standard for measuring body composition. It separates total body weight into fat mass, lean mass (muscle), and bone mineral content, with regional breakdowns for arms, legs, and trunk. A handheld bioelectrical impedance scale is convenient but is heavily affected by hydration and gives only broad estimates. A DEXA gives you actual numbers you can track over time, with enough precision to know whether you are losing the right tissue. 

How quickly does muscle come back after stopping a GLP-1 if I lost too much? 

Recovery depends on age, hormonal status, protein intake, and training. In our experience, women in perimenopause and menopause without hormone optimization tend to find it harder to protect their muscle, even with deliberate effort. Hormone therapy supports muscle maintenance, which is why we focus on protecting lean mass before and during a GLP-1. The simplest answer is that prevention is dramatically easier than recovery, which is why we measure a baseline DEXA before starting any GLP-1. 

Do you offer GLP-1 medications as a standalone service? 

No. We only prescribe GLP-1 medications inside our comprehensive hormone optimization and longevity program. The reason is in the data above: a GLP-1 prescription without hormone optimization, body composition tracking, protein guidance, and a clear off-ramp produces outcomes we are not willing to be responsible for. If you are looking for a standalone GLP-1 prescription, there are telehealth services that will provide one. If you are looking for a sustainable weight loss outcome with intact muscle and a strong metabolic baseline at the end, we are one of a small number of clinics in Utah doing this work comprehensively. For more about how we work with patients, see our patient FAQs. 

Ready to find out what is actually happening in your body? 

Comprehensive hormone optimization, DEXA-verified body composition, and GLP-1 medication when clinically indicated. At our Sandy, Utah clinic. The full program, not just a prescription. 

SCHEDULE A FREE CONSULTATION AT OUR SANDY, UTAH CLINIC →

References 

Hurtado MD, Tama E, Fansa S, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024 Apr;31(4):266-274. https://pubmed.ncbi.nlm.nih.gov/38446869/ 

Castaneda R, Bechenati D, Hurtado MD, et al. Tirzepatide-associated weight loss outcomes by menopausal hormone therapy use in postmenopausal women. The Lancet Obstetrics, Gynaecology, and Women’s Health. January 2026. (Findings initially presented at ENDO 2025 and the Menopause Society 2025 Annual Meeting.) 

Muscle mass loss during GLP-1 receptor agonist therapy. Nature Reviews Endocrinology. 2025. https://www.nature.com/articles/s41574-025-01140-w 

RAND Corporation. GLP-1 Agonists in Perimenopause: Unique Risks and Potential Opportunities. August 2025. https://www.rand.org/pubs/commentary/2025/08/glp-1-agonists-in-perimenopause-unique-risks-and-potential.html 

Mayo Clinic News Network. New study links combination of hormone therapy and tirzepatide to greater weight loss after menopause. https://newsnetwork.mayoclinic.org/discussion/new-study-links-combination-of-hormone-therapy-and-tirzepatide-to-greater-weight-loss-after-menopause/ 

Reviewed by Nicole Kelly, PA-C  ·  Medical Director, Revitalize Medical Solutions  ·  Sandy, Utah  ·  All clinical claims verified prior to publication  ·  Patient case study presented with details adjusted to protect privacy  ·  Document version 4.1

Related Articles

A Complete Guide to Functional Medicine for Energy, Weight Loss, and Hormone Balance

Functional medicine focuses on identifying underlying factors that may contribute to low energy, weight concerns, and hormone imbalance. Instead of focusing solely on symptoms, it emphasizes a whole-body approach that considers lifestyle, nutrition, and metabolic health. At Revitalize Medical Solutions, care is centered on helping individuals better understand their health through personalized evaluation tools and…

Pexels nappy 2362887 (2)

Menopause and Heart Disease: Why the FDA Just Reversed Twenty Years of Hormone Therapy Warnings, and What It Means for Sandy, Utah Women 

Heart disease kills more American women than every cancer combined. The risk accelerates sharply at menopause. For more than two decades, women were warned away from the one intervention that could have protected them. In November 2025, the FDA reversed course. Here is what the actual research shows about hormone therapy and women's cardiovascular health,…

Smiling,Older,Woman,Looks,At,Tablet,With,Hands,Under,Chin,

Which hormone quiz is right for you?

Choose the path that fits you. Each assessment takes about two minutes.

custom

Female Hormone Optimization

Explore whether hormone changes may be behind how you feel.

Take the Women's Quiz
custom

Male Hormone Optimization

See whether low hormones may be affecting energy, mood, and strength.

Take the Men's Quiz